Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder

References

• . Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008
   Google Scholar
• American Diabetes Association. Management. In: Burant CF, ed. Medical Management of Type 2 Diabetes. 6th ed. Alexandria, VA: American Diabetes Association; 2008:33–85
   Google Scholar
• . American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596–615
   PubMed Web of Science ®Google Scholar
• . International Diabetes Federation. Diabetes prevalence. http://www.idf.org/home/index.cfm?node=264. Accessed May 26, 2009
   Google Scholar
• . Fowler MJ. Microvacular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82
   Google Scholar
• . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
   PubMed Web of Science ®Google Scholar
• . International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed May 26, 2009
   Google Scholar
• . Stonehouse AH, Holcombe H, Kendall DM. GLP–1 analogues, DPP-IV inhibitors, and the metabolic syndrome. In Fonseca V, ed. Therapeutic Strategies in Metabolic Syndrome. Oxford, UK: Atlas Medical Publishing; 2008:137–157
   Google Scholar
• . Ho JS, Cannaday JJ, Barlow CE, Mitchell TL, Cooper KH, FitzGerald SJ. Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol. 2008;102(6):689–692
   PubMed Web of Science ®Google Scholar
• . Eeg-Olofsson K, Cederholm J, Nilsson PM, . Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13 087 patients. Diabetologia. 2009;52(1):65–73
   PubMed Web of Science ®Google Scholar
• . Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31(8):1582–1584
   PubMed Web of Science ®Google Scholar
• . Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9( Suppl 4):326S–334S
   Google Scholar
• . Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;23;339(4):229–234
   Google Scholar
• . Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28(12):2901–2907
   PubMed Web of Science ®Google Scholar
• . Stratton IM, Adler AI, Neil HAW, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–112
   PubMed Web of Science ®Google Scholar
• . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–713
   PubMed Web of Science ®Google Scholar
• . Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22(5):331–339
   PubMed Web of Science ®Google Scholar
• . Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol. 2008;18(3):222–229
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, .; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13( Suppl 1):1–68
   PubMedGoogle Scholar
• . Henry RR. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. Curr Med Res Opin. 2008;24(8):2189–2202
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994–2007. Arch Intern Med. 2008;168(19):2088–2094
   PubMedGoogle Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). United Kingdom Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . ; Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein HC, Miller ME, Byington RP, . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, .; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO, .; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192
   PubMed Web of Science ®Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase–4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082
   PubMed Web of Science ®Google Scholar
• . Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46(12):1954–1962
   PubMed Web of Science ®Google Scholar
• . Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199–E206
   PubMed Web of Science ®Google Scholar
• . Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47(3):357–366
   PubMed Web of Science ®Google Scholar
• . Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC–1 cells. Endocrinology. 1992;130(1):159–166
   PubMed Web of Science ®Google Scholar
• . Farilla L, Hui H, Bertolotto C. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143(11):4397–1408
   PubMed Web of Science ®Google Scholar
• . Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP–4 inhibitors. Curr Diabetes Rev. 2008;4(2):101–109
   PubMedGoogle Scholar
• . Nauck MA, Heimesaat MM, Behle K, . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–1246
   PubMed Web of Science ®Google Scholar
• . Gutzwiller JP, Göke B, Drewe J, . Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44(1):81–86
   PubMed Web of Science ®Google Scholar
• . Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829–835
   PubMedGoogle Scholar
• . Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929–2940
   PubMed Web of Science ®Google Scholar
• . Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585–3596
   PubMed Web of Science ®Google Scholar
• . Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52
   PubMed Web of Science ®Google Scholar
• . Toft-Nielsen MB, Damholt MB, Madsbad S, . Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717–3723
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type–2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307
   PubMed Web of Science ®Google Scholar
• . Kolterman OG, Kim DD, Shen L, . Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62(2):173–181
   PubMed Web of Science ®Google Scholar
• . Froud T, Faradji RN, Pileggi A, . The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86(1):36–45
   PubMed Web of Science ®Google Scholar
• . Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002;51(5):1443–1452
   PubMed Web of Science ®Google Scholar
• . Bunck MC, Diamant M, Cornér A, . One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762–768
   PubMed Web of Science ®Google Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . Buse JB, Klonoff DC, Nielsen LL, . Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29(1):139–153
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Zinman B, Hoogwerf BJ, Durán García S, . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Burger J, Johns D, . Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333–2348
   PubMed Web of Science ®Google Scholar
• . Glass LC, Qu Y, Lenox S, . Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin. 2008;24(3):639–644
   PubMed Web of Science ®Google Scholar
• . Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559–569
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Duran S, Kim D. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia. 2007;50(2):259–267
   PubMed Web of Science ®Google Scholar
• . Bergenstal RM, Kim T, Trautmann M, Zhuang D, Okerson T, Taylor K. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes. Circulation. 2008;118( Suppl 1):S1086. Abstract 1239
   Web of Science ®Google Scholar
• . DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943–2952
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Buse JB, Taylor K, .; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Kim D, MacConell L, Zhuang D, . Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–1493
   PubMed Web of Science ®Google Scholar
• . Klonoff DC, Buse JB, Nielsen LL, . Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275–286
   PubMed Web of Science ®Google Scholar
• . Moretto TJ, Milton DR, Ridge TD, . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460
   PubMed Web of Science ®Google Scholar
• . Austin RP. Polypharmacy as a risk factor in the treatment of type 2 diabetes. Diabetes Spectrum. 2006;19(1):13–16
   Google Scholar
• . Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7(6):722–728
   PubMed Web of Science ®Google Scholar
• . Leenen FH, Wilson TW, Bolli P, . Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13(10):914–920
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R, .; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brändle M, .; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Nauck M, Frid A, Hermansen K, .; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161–168
   PubMed Web of Science ®Google Scholar
• . Vilsbøll T, Zdravkovic M, Le-Thi T, . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–1610
   PubMed Web of Science ®Google Scholar
• . Courrèges JP, Vilsbøll T, Zdravkovic M, . Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med. 2008;25(9):1129–1131
   PubMed Web of Science ®Google Scholar
• . Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol. 2009;8:12
   PubMed Web of Science ®Google Scholar
• . Stonehouse AH, Holcombe JH, Kendall DM. Management of type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother. 2006;7(15):2095–2105
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32( Suppl 1):S13–S61
   PubMed Web of Science ®Google Scholar
• . Blank RC, Brunton S. Managing multiple cardiovascular risk factors. J Fam Pract. 2008;57( 3 Suppl):S13–S20
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB, .; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar